SCHEDULE: FMR LLC Discloses 5.9% Stake in CytomX Therapeutics
Beneficial Ownership Disclosure (Schedule 13G)
FMR LLC and its affiliates, including Abigail P. Johnson, have disclosed a 5.9% beneficial ownership stake in CytomX Therapeutics Inc. common stock.
Summary
- FMR LLC and its affiliates, including Abigail P. Johnson, reported beneficial ownership of 9,238,868 shares of CytomX Therapeutics Inc. common stock as of June 30, 2025.
- This represents 5.9% of the total outstanding common stock of CytomX Therapeutics Inc.
- The filing was made under Rule 13d-1(b) on August 5, 2025, indicating the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
- FMR LLC holds sole voting power over 9,238,690 shares and sole dispositive power over 9,238,868 shares.
- Abigail P. Johnson holds sole dispositive power over 9,238,868 shares, with no sole or shared voting power directly attributed to her in the filing.
Sentiment
Score: 6
Explanation: The filing is neutral in tone as it is a factual disclosure of beneficial ownership. However, the acquisition of a significant stake (5.9%) by a major institutional investor like FMR LLC can be interpreted as a positive signal of confidence in the company, hence a slightly positive score.
Positives
- A significant institutional investor, FMR LLC, has taken a substantial 5.9% stake in CytomX Therapeutics, potentially signaling confidence in the company's long-term prospects.
- The filing indicates the stake is held in the ordinary course of business, suggesting a passive investment rather than an activist intent to influence control.
Negatives
- No specific negatives are disclosed in this beneficial ownership filing.
Risks
- No specific risks related to CytomX Therapeutics' operations or financial health are detailed in this beneficial ownership filing. The filing itself is a disclosure of an investment, not a risk assessment of the underlying company.
Future Outlook
NA
Industry Context
This filing indicates a significant investment by a major asset management firm, FMR LLC, into a biotechnology company, CytomX Therapeutics. Such investments are common in the biotech sector, which often requires substantial capital and can attract institutional interest due to potential for high growth or innovative drug development. The disclosure of a 5.9% stake suggests FMR LLC views CytomX as a notable holding within its portfolio.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Internal Governance Structure Disclosure | Disclosure of the Johnson family's predominant ownership (49% voting power) of FMR LLC's Series B voting common shares and a shareholders' voting agreement, which results in the family being deemed a controlling group for FMR LLC. | NA | Clarifies the control structure of the reporting entity, FMR LLC, which indirectly controls the voting and dispositive power over the reported shares of CytomX Therapeutics. |
Stakeholder Impact
- Shareholders: The disclosure of a significant stake by a major institutional investor like FMR LLC could be viewed positively by existing shareholders, potentially indicating validation of the company's value.
- Investment Community: Provides transparency regarding a large institutional holding, which can influence market perception and trading activity.
Key Dates
| Date | Description |
|---|---|
| 05/23/2023 | Effective date of Power of Attorney for Richard Bourgelas, authorizing signatures on behalf of FMR LLC and Abigail P. Johnson. |
| 08/08/2023 | Date of previous Schedule 13G filing by FMR LLC, where the Power of Attorney (Exhibit 24) was incorporated by reference. |
| 06/30/2025 | Date of event which required the filing of this statement, indicating the beneficial ownership threshold was met or exceeded. |
| 08/05/2025 | Date of signing and filing of this Schedule 13G. |
Keywords
CytomX Therapeutics, FMR LLC, Abigail P. Johnson, Beneficial Ownership, Schedule 13G, Common Stock, Biotechnology, Investment, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.